Skip to main content

Table 2 Comparisons of characteristics between chemotherapy group and control group 2 in matched 3570 HR-positive, Her-2-negative, pT1b-c/N0–1/M0 ILC patients

From: Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0–1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database

   Control (n = 1785) Chemotherapy (n = 1785) Statistical value P bias t-test for bias P
Age (years) < 40 37 (2.07%) 47 (2.63%) χ2 = 15.831 0.003 −11.6 −3.48 0.001
40–49 319 (17.87%) 392 (21.96%)
50–59 588 (32.94%) 605 (33.89%)
60–69 646 (36.19%) 557 (31.20%)
70–79 195 (10.92%) 184 (10.31%)
Race Black 162 (9.08%) 174 (9.75%) χ2 = 0.170 0.919 −3.7 −1.08 0.280
White 1493 (83.64%) 1495 (83.75%)
Other 130 (7.28%) 116 (6.50%)
Tumor Ib 389 (21.79%) 374 (20.95%) χ2 = 0.375 0.540 1.9 0.61 0.540
Ic 1396 (78.21%) 1411 (79.05%)
LN N0 907 (50.81%) 895 (50.14%) χ2 = 0.161 0.688 1.6 0.40 0.688
N1 878 (49.19%) 890 (49.86%)
Grade I 450 (25.21%) 430 (24.09%) z = −0.762 0.446 2.5 0.75 0.456
II 1173 (65.71%) 1188 (66.55%)
III 162 (9.08%) 167 (9.36%)
Radiotherapy No 938 (52.55%) 883 (49.47%) χ2 = 3.391 0.066 6.2 1.84 0.066
Yes 847 (47.45%) 902 (50.53%)
Surgery No surgery 34 (1.90%) 36 (2.02%) χ2 = 3.392 0.183 5.5 1.59 0.112
BCS 897 (50.25%) 842 (47.17%)
Mastectomy 854 (47.84%) 907 (50.81%)